Skip to main content

Table 3 Baseline tumor features and treatments in patients with disease confined to a single organ a

From: Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination

Variable Overall,N(%) CTCs <5/7.5 ml,n(%) CTCs ≥5/7.5 ml,n(%) P-value
Overall population 146 (100) 104 (71.2) 42 (28.8) -
HR status     
Positive 99 (67.8) 67 (64.4) 32 (76.2) ns
Negative 47 (32.2) 37(35.6) 10 (23.8)
HER2 status     
HER2 amplified/overexpressed 30 (20.6) 22 (21.2) 8 (19.1) ns
HER2 normal 116 (79.4) 82 (78.8) 34 (80.9)
Treatment strategy     
Systemic treatment only 129 (88.4) 91 (87.5) 38 (90.5) ns
Additional locoregional treatment 17 (11.6)b 13 (12.5) 4 (9.5)
Type of systemic treatment     
Chemotherapy 101 (69.2) 70 (67.3) 31 (73.8) ns
Endocrine therapy 41 (28.1) 31 (29.8) 10 (23.8)
Other 4 (2.7) 3 (2.9) 1 (2.4)
Distribution of metastatic sites     
Lymph nodes/soft tissues 50 (34.2) 41 (39.4) 9 (21.4) 0.023
Bone 68 (46.6) 41 (39.4) 27 (64.3)
Viscera 28 (19.2) 22 (21.2) 6 (14.3)
  1. aCTCs, Circulating tumor cells; HER2, Human epidermal growth factor receptor 2; HR, Hormone receptor; ns, Statistically nonsignificant. bAdditional locoregional treatments: surgery in 12 patients (8.2%), radiation therapy in 4 patients (2.7%) and other for 1 patient (0.7%).